Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down before the market opened on Monday . The stock had previously closed at $49.0192, but opened at $39.92. Zealand Pharma A/S shares last traded at $38.75, with a volume of 9,921 shares trading hands.

Analyst Ratings Changes

Several equities research analysts have recently commented on ZLDPF shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Finally, BNP Paribas Exane lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Stock Up 7.9%

The company’s fifty day moving average is $47.94 and its 200-day moving average is $58.85. The company has a market capitalization of $3.01 billion, a PE ratio of 3.12 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.50. The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $2.81 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%. As a group, analysts predict that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.